The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity
- PMID: 30353552
- DOI: 10.1111/apt.15015
The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity
Abstract
Background: Metabolically healthy obesity (MHO) shows a reduced risk compared with obese patients with adverse metabolic conditions. Lean people suffering some metabolic derangements also have non-alcoholic fatty liver disease (NAFLD)-related outcomes compared with non-obese subjects with a few metabolic risks.
Aim: To define the impact of the metabolic status on the NAFLD-related outcomes, beyond the presence of obesity.
Methods: We designed a multicentre cross-sectional study, including 1058 biopsy-proven NAFLD patients. Metabolically healthy status was strictly defined by the lack of metabolic risk factors (diabetes mellitus, low HDL, hypertriglyceridemia, arterial hypertension). Non-alcoholic steatohepatitis (NASH) and significant fibrosis (F2-F4) were identified by liver biopsy. Chronic kidney disease epidemiology collaboration equation was calculated for kidney function and the atherogenic index of plasma (AIP) for cardiovascular risk.
Results: Metabolically healthy (OR 1.88; P = 0.050) and unhealthy obesity (OR 3.47: P < 0.0001), and unhealthy non-obesity (OR 3.70; P < 0.0001) were independently associated with NASH together with homeostatic model assessment (HOMA), ALT, and platelets. Significant fibrosis was more frequently observed in the presence of adverse metabolic conditions in obese (OR 3.89; P = 0.003) and non-obese patients (OR 3.92; P = 0.002), and independently associated with platelets, albumin, ALT, HOMA, and age. The number of metabolic factors determined the risk of NASH and significant fibrosis. Glomerular filtration rate was lower in unhealthy (91.7 ± 18) than healthy metabolism (95.6 ± 17) (P = 0.007). AIP was higher in adverse metabolic conditions (P = 0.0001). Metabolically unhealthy non-obesity showed higher liver damage (NASH 55.8% vs 42.4%; P < 0.05; significant fibrosis 31.7% vs 11.4%; P < 0.0001) and cardiovascular risk (P < 0.0001) than healthy obesity.
Conclusions: Metabolic unhealthy status showed a greater impact on NASH, significant fibrosis, kidney dysfunction, and atherogenic profile than obesity. However, metabolically healthy obesity was not a full healthy condition. We should focus our messages especially on patients with adverse metabolic conditions.
© 2018 John Wiley & Sons Ltd.
Similar articles
-
Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.Clin Gastroenterol Hepatol. 2017 Oct;15(10):1604-1611.e1. doi: 10.1016/j.cgh.2017.04.045. Epub 2017 May 26. Clin Gastroenterol Hepatol. 2017. PMID: 28554682
-
Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH.J Hepatol. 2020 Jul;73(1):17-25. doi: 10.1016/j.jhep.2020.02.028. Epub 2020 Mar 6. J Hepatol. 2020. PMID: 32147361
-
Obesity is more closely related with hepatic steatosis and fibrosis measured by transient elastography than metabolic health status.Metabolism. 2017 Jan;66:23-31. doi: 10.1016/j.metabol.2016.10.003. Epub 2016 Oct 15. Metabolism. 2017. PMID: 27923446
-
Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity.Ann Hepatol. 2020 Jul-Aug;19(4):359-366. doi: 10.1016/j.aohep.2020.03.001. Epub 2020 Mar 21. Ann Hepatol. 2020. PMID: 32349939 Review.
-
Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies.PLoS Med. 2020 Apr 30;17(4):e1003100. doi: 10.1371/journal.pmed.1003100. eCollection 2020 Apr. PLoS Med. 2020. PMID: 32353039 Free PMC article.
Cited by
-
Delicate and thin fibrous septa indicate a regression tendency in metabolic dysfunction-associated steatohepatitis patients with advanced fibrosis.Hepatol Int. 2025 Feb;19(1):166-180. doi: 10.1007/s12072-024-10719-w. Epub 2024 Aug 16. Hepatol Int. 2025. PMID: 39152361
-
The presence of NAFLD in nonobese subjects increased the risk of metabolic abnormalities than obese subjects without NAFLD: a population-based cross-sectional study.Hepatobiliary Surg Nutr. 2021 Dec;10(6):811-824. doi: 10.21037/hbsn-20-263. Hepatobiliary Surg Nutr. 2021. PMID: 35004947 Free PMC article.
-
Impact of PNPLA3 I148M on Clinical Outcomes in Patients With MASLD.Liver Int. 2025 Mar;45(3):e16133. doi: 10.1111/liv.16133. Epub 2024 Oct 16. Liver Int. 2025. PMID: 39412170 Free PMC article. Review.
-
Global prevalence, metabolic characteristics, and outcomes of lean-MAFLD: a systematic review and meta-analysis.Hepatol Int. 2025 Jun;19(3):607-618. doi: 10.1007/s12072-025-10801-x. Epub 2025 Mar 14. Hepatol Int. 2025. PMID: 40087205 Free PMC article.
-
Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention.Cardiovasc Diabetol. 2022 Dec 3;21(1):270. doi: 10.1186/s12933-022-01697-0. Cardiovasc Diabetol. 2022. PMID: 36463192 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous